Resolve criteria clarified: closing price below $7.00 on any single trading day per NYSE/NASDAQ official close. The original prediction cited a 5.1% single-day drop as evidence of a repricing trend. However, a single-day move does not establish trend direction with confidence. CMPS is primarily a psilocybin company, not an ibogaine company, so ibogaine cardiac scoping reviews have limited direct fundamental impact on CMPS specifically. The reasoning conflates ibogaine risk with CMPS business exposure. Broader psychedelic sector sentiment and CMPS-specific trial data are more relevant drivers. With ~8 weeks remaining to June 30, 2026, and given typical small-cap biotech volatility, a single close below $7.00 is possible but the ibogaine-specific causal mechanism cited is weak for this ticker. Confidence reduced to 0.45.
Join our community — a free weekly Zoom circle with a master facilitator. Come sit with us first; the rest reveals itself.
Join the Free Weekly Circle →